Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval

Por: MarketWatch Politics February 14, 2023

thumbnail

At that time, there was growing interest in better understanding nonalcoholic fatty liver disease (NAFLD), a range of conditions that occurs when excess fat builds up in liver cells. An estimated 25% of Americans have NAFLD, while about 20% of those patients end up developing a more severe version called nonalcoholic steatohepatitis (NASH), in which the inflammation and cell damage caused by the fat buildup can cause cirrhosis and liver... + full article



Similar News

House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug

Politico USA Health December 30, 2022

thumbnailThe FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House... + más

Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times

Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News


Report: FDA and Biogen brought Alzheimer's drug to market despite internal concerns

ABC7 USA World December 30, 2022

thumbnailA congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency deviated from its standard procedures to approve the Aduhelm drug with inconsistent data.Aduhelm is notable for being the first drug... + más

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes

Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times


Brooklyn Nets' Steve Nash ejected for first time as coach

ABC News USA Sports October 27, 2022

thumbnailMILWAUKEE -- coach Steve Nash was ejected for the first time in his coaching career during the third quarter of Wednesday night's to the .Nash seemed frustrated by several calls throughout the night, but his frustration boiled over with 4:24 left in the third. He said after... + más

Steve Nash booed at Nets Practice in the Park | New York Daily News

Bucks use lopsided run after Nash ejected, beat Nets 110-99 | WPLG Local 10


Steve Nash booed at Nets Practice in the Park

New York Daily News USA Sports October 10, 2022

thumbnailA record-setting and capacity-reaching 8,000 fans packed Pier 2 at Brooklyn Bridge Park for the Nets’ fifth annual Practice in the Park on Sunday. And of those fans, around a quarter of them booed head coach Steve Nash when he was introduced to the crowd. Nash was the final... + más

Brooklyn Nets coach Steve Nash says he's cleared the air with Kevin Durant after tumultuous summer | ABC News

Steve Nash says relationship with Kevin Durant is fine: ‘Families have issues’ | New York Daily News


ALS drug wins FDA approval despite questionable data

ABC News USA Health September 30, 2022

thumbnailWASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | WPLG Local 10


Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval

New York Post USA Life September 30, 2022

thumbnailA much-debated drug for Lou Gehrig’s disease won US approval on Thursday from the Food and Drug Administration. The nod represents a long-desired victory for patients, though it is likely to renew questions about the scientific rigor behind government reviews of... + más

ALS drug wins FDA approval despite questionable data | ABC News

ALS drug gets FDA approval despite uncertainty about effectiveness | ABC7


FDA approves controversial new drug designed to slow the progression of ALS

CNBC USA Health September 29, 2022

thumbnailThe Food and Drug Administration on Thursday approved a controversial new drug designed to slow the progress of Lou Gehrig's disease, a victory for patients and advocates despite limited evidence that the drug is effective.The drug, from the Massachusetts-based , joins... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News



About iurex | Privacy Policy | Disclaimer |